You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Image-based risk assessment to identify women at high-risk for breast cancer

    SBC: WAVED MEDICAL LLC            Topic: NCI

    7. PROJECT SUMMARY Breast cancer is the most common cancer worldwide and the most common cancer diagnosed in American women. While there has been good progress regarding detection and treatment methods, breast cancer remains the primary cause of death from malignant tumors. Hence, there is a critical need for the development of novel predictive and prognostic factors. Risk assessments are currentl ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia

    SBC: FGF Therapeutics INC.            Topic: NIAMS

    Abstract Hyperphosphatemic familial tumoral calcinosis (hfTC) is a disease in which patients cannot produce the bioactive form of the hormone Fibroblast growth factor-23 (FGF23), which is secreted by osteocytes to rid the body of phosphate by acting on the kidney. hfTC is characterized by markedly elevated serum phosphate (Pi) which causes large intramuscular calcifications to develop. The calcifi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Preclinical evaluation of SERCA2 allosteric activators for pancreatic β-cell protection in diabetes.

    SBC: NEURODON, LLC            Topic: NIDDK

    The overall goal of this collaborative project between Neurodon and Indiana University School of Medicine is the development of compounds that will offer disease-modifying treatments for type 1 (T1D) and type 2 diabetes (T2D) mellitus, a sorely unmet need. In this initial STTR project, we will use our expertise in medicinal chemistry, cell biology, and diabetes pathophysiology to functionally test ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Virtual Reality Facilitation of Recovery from Opioid Use Disorder

    SBC: RELATE XR, LLC            Topic: NIDA

    PROJECT SUMMARY / ABSTRACT This Phase I project is a pilot randomized clinical trial designed to show commercial potential for a novel virtual reality intervention in preparation for Phase II development. We propose testing our adjunctive intervention for efficacy on reducing opioid use and increasing abstinence in early recovering opioid use disorder (OUD) persons, with concomitant increases in s ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. The Butterfly BVM, a Novel Resuscitator to Prevent Hyperventilation in Pediatric Resuscitation

    SBC: COMPACT MEDICAL INC.            Topic: NICHD

    PROJECT SUMMARY Bag-valve-mask (BVM) resuscitators are difficult to use correctly and are commonly misused, even by trained medical personnel. Misuse can result in serious injury and death due to volutrauma or barotrauma, and this is particularly concerning when resuscitating pediatric patients, in whom there is an extreme range in lung volume. Traditional BVMs provide no adequate means of restric ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Personalized dosing of dichloroacetate for the treatment of rare and common diseases

    SBC: Medosome Biotec, LLC            Topic: NICHD

    Project Abstract/Summary Pyruvate dehydrogenase complex (PDC) deficiency (PDCD) is a rare disease of mitochondrial energy failure in which the life expectancy of affected children is severely truncated from unrelenting lactic acidosis and/or from progressive neurological and neuromuscular degeneration. Treatment of PDCD remains a serious, unmet, challenge. Dichloroacetate (DCA) represents the firs ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. From Academia to Business: Development of Novel Therapeutics Against HPV-Associated Cancer

    SBC: Kovina Therapeutics Inc.            Topic: NCI

    ABSTRACT “High-risk” human papillomavirus (HPV) types such as 16 (HPV-16) are identified in the majority of HPV- associated pre-malignant and malignant pathologies of cervical, anogenital, and oropharyngeal epithelia. The E6 protein is essential for viral replication. Structure-based computational screening followed by design and synthesis of derivatives led to the identification of a series o ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. New Treatments for Glaucoma

    SBC: GRANNUS THERAPEUTICS, INC.            Topic: NEI

    Abstract Aggregation of mutated myocilin (MYOC), a protein found in the endoplasmic reticulum (ER) of trabecular meshwork (TM) cells, disrupts the outflow of aqueous humor from the eye, causing increase in intraocular pressure (IOP), progressive retinal ganglion cell (RGC) death, and degeneration of the optic nerve, leading to primary open-angle glaucoma (POAG), characterized by irreversible visio ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Develop and Commercialize the Bayesian Dose-Response Modeling System and Services

    SBC: KS & ASSOCIATES LLC            Topic: NIEHS

    PROJECT SUMMARY Chemical risk assessment is widely applied in industries and regulatory agencies as an important tool to evaluate chemical toxicity in support of chemical registration, safety evaluation, and exposure limitation development. One of the most notable improvements in dose-response assessment - a required quantitative step in risk assessment - is the development of benchmark dose (BMD) ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Avoiding Adverse Opioid Outcomes with Proactive Precision Care

    SBC: OpalGenix, Inc.            Topic: NIDA

    PROJECT SUMMARY FOR PREDICATE STTR PHASE I GRANT Perioperative and prescribed opioids often result in costly and unpredictable adverse effects, including life threatening respiratory depression and long-term opioid use/misuse in vulnerable patients. The US FDA warns against the use of codeine and tramadol in children due to postoperative anoxic brain injuries and deaths, and in nursing mothers due ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government